EGX-B

EGX-B is a novel, small-molecule serotonin 5-HT2A receptor agonist being developed by atai Life Sciences in collaboration with EntheogeniX Biosciences for the treatment of depressive disorders. Unlike traditional tryptamine-based psychedelics, EGX-B features a non-tryptamine chemical structure and exhibits high selectivity (greater than 100-fold) for the 5-HT2A receptor over the 5-HT2B receptor, potentially reducing the risk of valvular heart disease associated with 5-HT2B activation. Preclinical studies have demonstrated that EGX-B is more potent than psilocin and induces the head-twitch response in rodents, a standard behavioral marker for psychedelic activity. As of late 2023, the compound remains in the preclinical research stage.